Comparison of dissolution release of commercially available extended release carbamazepine tablets in Iraqi drug market using in vitro USP II method

  • Tara Abdulrahman Abdullah Department of Pharmaceutics, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Adnan Burhan Qader Department of Pharmaceutics, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Keywords: Anti-epileptics, Carbamazepine E.R, Dissolution rate, Brand product, Generic products.

Abstract

Background and objective: Carbamazepine is widely used as an anti-epileptic drug, primarily for the treatment of partial and tonic-clonic seizures. The drug is absorbed slowly and variably after oral administration due to its limited water solubility. In clinics, single daily dosing of conventional dosage forms of carbamazepine is insufficient; effective levels are provided by the multiple-dose administration. A multiplicity of dosage causes inconsistent plasma levels leading to side effects because of its narrow therapeutic range and toxicity levels. A single dose of extended release dosage forms is suggested to keep levels within the therapeutic concentrations. This study aimed to compare the in vitro behavior of generic tablets containing carbamazepine with the brand product.

Methods: Basket apparatus was used to evaluate in vitro behavior of the different products and similarity test was applied to evaluate the differences between generic products and the brand. The study and test were carried out in Jun 2014 at the College of Pharmacy, Hawler Medical University.  

Results: There was a significant difference between the in vitro behavior of one of the generic products in the study and the in vitro behavior of the brand product.  

Conclusions: The in vitro study using basket apparatus could be considered as an effective method to evaluate the in vitro behavior of the majority of pharmaceutical dosage forms. In vitro behavior is a direct indicator for in vivo one. Therefore the quality of the medicaments could be evaluated and the risk to the patients could be significantly reduced. 

References

McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE. The Pharmacological Basis of Therapeutics, 10th ed.; McGraw-Hill: New York Goodman & Gilman’s; 2001. P. 533-4.

Beghi E. Carbamazepine: clinical efficacy and use in other neurological disorders. In: Levy R, Mattson R, Meldrum B, Penry J, Dreifuss F.Antiepileptic drugs, 5th ed. Lippincott, Philadelphia: Williams & Wilkins; 2002. P. 273-7.

Trimble MR. Carbamazepine: clinical efficacy and use in psychiatric disorders. In: Levy R, Mattson R, Meldrum B, Penry J, Dreifuss F. Antiepileptic drugs, 5th ed. Lippincott, Philadelphia: Williams & Wilkins; 2002. P. 278-84.

Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychophar-macol 2003; 23:182-92.

Wael A, Alia B, Mahmoud M, Hanan E N. Formulation and evaluation of carbamazepine 200 mg chewable tablets using cyclodextrins. IJPPS 2012; 4(4):472-80.

Geradin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacoki-netics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm 1976; 4:521-35.

McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981; 3:63-70.

Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36 (Suppl. 5):S8-13.

Koester LS, Ortega GG, Mayorga PP, Bassani VL. Mathematical evaluation of in vitro release profiles of hydroxyl-propyl methylcellulose matrix tablets containing carbamazepine associated with B-cyclodextrin. Eur J Pharm Biopharm 2004; 58(1):177-9.

Barakat NS, Elbagory IM, Almurshedi AS. Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine: AAPS Pharm Sci Tech 2008; 3:931-8.

Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clin Pharmacokinet 1992; 22(1):1-21.

Ikegami K, Tagawa K, Kbayashi M, Osawa T. Prediction of in vivo drug release behaviour of controlled-release multiple-unite dosage forms in dogs using a flow-through type dissolution test method. Int J Pharm2003; 258:31-43.

Pharmacopeia U. United States Pharmacopeia And National Formulary (Usp 28–Nf 23). The United States Pharmacopeial Convention, Inc.: Rockville; 2005. 341-4, 2411-20, 2501-10, 2670.

Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods. Int J Pharm 2000; 209:57-67.

Costa P, Jose MSL. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13:123-33.

Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Tech 1996; 20 (6):64-70.

Published
2018-08-30
How to Cite
Abdullah, T., & Qader, A. (2018). Comparison of dissolution release of commercially available extended release carbamazepine tablets in Iraqi drug market using in vitro USP II method. Zanco Journal of Medical Sciences (Zanco J Med Sci), 20(2), 1288 - 1293. https://doi.org/10.15218/zjms.2016.0022
Section
Original Articles